JTE 607 dihydrochloride is a cytokine release inhibitor. JTE 607 dihydrochloride inhibits production of IL-1β, IL-8, IL-6, IL-10 and TNFα from LPS-stimulated PBMCs with IC50 values are 5.9, 7.3, 8.8, 9.1 and 11.0 nM, respectively. JTE 607 dihydrochloride reduces proinflammatory cytokine-release and attenuates lung permeability in a rat lung injury model. JTE-607 induces apoptosis in leukemia cells in vitro and prolongs survival in a mouse leukemia model.
Molecular Weight | 597.36 |
Formula | C25H31Cl2N3O5.2HCl |
CAS Number | 188791-09-5 |
Solubility (25°C) | DMSO 100 mg/mL Water ≥ 20 mg/mL |
Storage | -20°C, dry, sealed |
Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
Related IL Receptor/Related Products |
---|
HB0017
HB0017 is a monoclonal antibody that targets interleukin-17 (IL-17) and selectively binds IL-17A, thereby preventing IL-1717A from binding to its receptor. |
Rademikibart
Rademikibart is a human IgG4ҡ monoclonal antibody that targets IL-4 Rα to block inflammatory signaling induced by IL-4 and IL-13, two important cytokines that drive allergic inflammation, and binds to the human IL-4Rα epitope with a KD of 20.7 pM. Rademikibart does not bind to IL-4Rα from other species. Rademikibart does not bind to IL-4Rα of other species.Rademikibart inhibits IL-4 and IL-13-mediated STAT6 signaling, TF-1 cell proliferation, and TARC production in PBMC, and can be used in studies related to moderate-to-severe Th2 inflammatory diseases. |
Stapokibart
Stapokibart is a humanized monoclonal antibody targeting IL-4Rα that blocks the interaction of cytokines IL-4 and IL-13 with their co-receptor subunit, IL-4Rα. Stapokibart is able to interact with IL-4Rα in humans, cynomolgus monkeys, and rats, and can be used in atopic dermatitis research. |
Erepdekinra
Erepdekinra is an interleukin-17A (IL-17A) receptor antagonist. |
AF12198
AF12198 is a potent, selective and specific peptide antagonist for human type I interleukin-1 receptor (IL1-R1) (IC50=8 nM) but not the human type II receptor (IC50=6.7 µM) or the murine type I receptor (IC50>200 µM). |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.